Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: J Autism Dev Disord. 2018 Jul;48(7):2379–2395. doi: 10.1007/s10803-018-3495-z

Table 1.

Characteristics of cases and controls, study to explore early development

ASD (N = 599) % POP (N = 811) %
Child sex
  Male 81.30 53.14
  Female 18.70 46.86
Child race/ethnicity
  Non-Hispanic White 54.75 68.38
  Non-Hispanic Black 17.80 10.92
  Hispanic 13.39 11.17
  Asian 5.93 3.26
  Mixed 8.14 6.27
Age at hand scan (months)
  < 48 5.56 7.60
  48–59 37.54 32.88
  60+ 56.90 59.53
Maternal age at birth (years)
  ≤ 34 71.81 68.60
  35+ 28.19 31.40
Maternal education at birth (years)
  ≤ 15 48.41 33.83
  16+ 51.59 66.17
Birth order
  First birth 48.71 45.56
  Second birth or later 51.29 54.44
Gestational age
  Term 83.22 90.84
  Preterm (< 37 weeks) 16.78 9.16
Birth plurality
  Singleton 91.08 96.24
  Multiple birth 8.92 3.76
Any maternal infertility disorder diagnosed prior to index pregnancy
  Yes 20.45 14.95
  No 79.55 85.05
Any maternal use ovulation medications to help get pregnant
  Yes 9.94 9.28
  No 90.06 90.72
Any maternal use progesterone medications to help get pregnant or maintain pregnancy
  Yes 10.69 9.54
  No 89.31 90.46
Maternal pre-pregnancy BMI (kg/m2)
  < 25 56.33 64.40
  25.0–29.9 25.67 21.85
  ≥ 30 18.00 13.75
Maternal prenatal smoking
  No 90.97 95.97
  Yes 9.03 4.03

ASD Autism spectrum disorder case group, POP population control group, BMI body mass index

Data excluded due to missing values for individual factors. Missing values were 0% for child sex, 1–5% for maternal age, maternal education, birth order, gestational age and birth plurality, and maternal pre-pregnancy BMI, and 6–9% for maternal infertility conditions, ovulation induction medications, progesterone medications, and smoking